Barclays PLC Purchases 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 134.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,384 shares of the company’s stock after acquiring an additional 169,756 shares during the period. Barclays PLC owned 0.10% of Amneal Pharmaceuticals worth $2,466,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMRX. Rubric Capital Management LP lifted its position in shares of Amneal Pharmaceuticals by 12.4% during the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after purchasing an additional 1,179,830 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after buying an additional 641,405 shares during the last quarter. State Street Corp boosted its position in shares of Amneal Pharmaceuticals by 3.8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after acquiring an additional 127,753 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals by 1.9% in the second quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock worth $16,954,000 after acquiring an additional 50,000 shares during the last quarter. Finally, BlackBarn Capital Partners LP increased its position in Amneal Pharmaceuticals by 41.5% during the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after acquiring an additional 586,703 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AMRX. Piper Sandler raised their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Truist Financial lifted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research report on Friday, September 6th. Finally, StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Trading Up 0.8 %

NASDAQ AMRX opened at $7.85 on Thursday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -11.54 and a beta of 1.12. The stock’s 50 day moving average is $8.38 and its two-hundred day moving average is $7.96.

Insider Buying and Selling

In related news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 17.46% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.